ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aflibercept

Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.

Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 201286 company-led studies, 5 open or runningNext primary completion: Jul 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticalsits history only251 open or runningphase 4since Nov 2, 2012May 13, 2002none ahead
Bayerits history only230 open or runningphase 4since Apr 10, 2014Mar 12, 2008none ahead
Sanofiits history only200 open or runningphase 3since May 16, 2006Jan 30, 2006none ahead
Novartisits history only40 open or runningphase 4since Jul 22, 2016Jul 22, 2016none ahead
Amgenits history only31 open or runningphase 3since Feb 13, 2020Feb 13, 2020Jul 31, 2027phase 3 · NCT07614776
Sam Chun Dang Pharm.its history only20 open or runningphase 3since Jul 17, 2020Jul 17, 2020none ahead
AbbVieits history only11 open or runningphase 2since Mar 16, 2022Mar 16, 2022Jun 2031phase 2 · NCT05296447
AO GENERIUMits history only11 open or runningphase 3since Sep 18, 2026Sep 18, 2026May 2028phase 3 · NCT07844148
Bioeqits history only10 open or runningphase 3since Aug 11, 2020Aug 11, 2020none ahead
Cinnagenits history only10 open or runningphase 3since Sep 18, 2022Sep 18, 2022none ahead
The Emmes10 open or runningphase 3since Oct 22, 2013Oct 22, 2013none ahead

Also a collaborator on its studies: REGENXBIO and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of The Emmes only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 22, 2013First study: phase 3 study in Retinal Vein OcclusionFirst studyNCT01969708 · 362 enrolled · United States
  2. Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127

TargetBeta

PGF →VEGFA →read by rule
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule

Studies

The one study The Emmes leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01969708Retinal Vein Occlusion · United States3CompletedNov 2016362

How it is read

Names in the registry

  • “Aflibercept”, 9 entries
  • “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept”, 7 entries
  • “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries

Codes read as this program: BAY865321, SCD411.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.